Due to the frequent occurrence of chemotherapy resistance in RCC patients treated with targeted therapeutics, it is critical to provide alternative therapeutic options for those who may develop resistance to XPO1 inhibition with the strategy proposed in this study. This evidence concerns the gene XPO1 and renal cell carcinoma.